Dermata Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

DRMA$0.71-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

	September 30, 2026	December 31, 2025
(unaudited)
Assets:
Cash and cash equivalents	$4,822,357	$7,521,978
Restricted cash	200,000	-
Prepaid expenses and other current assets	583,314	341,848
Inventories	825,279	-
Total current assets	6,430,950	7,863,826
Property and equipment, net	158,904	-
Other assets	45,637	-
Total assets	$6,635,491	$7,863,826
Liabilities and Stockholders’ Equity:
Liabilities:
Accounts payable (including related party amounts of $51,983 and $86,250 as of September 30, 2026 and December 31, 2025, respectively)	$1,619,972	$460,811
Accrued and other current liabilities (including related party amounts of $0 and $25,000 as of September 30, 2026 and December 31, 2025, respectively)	1,109,593	1,179,635
Total liabilities	2,729,565	1,640,446
Commitments and Contingencies (see Note 6)	-	-
Stockholders’ Equity:
Common Stock, par value $0.0001, 250,000,000 shares authorized; 4,930,207 shares issued and outstanding as of September 30, 2026; 2,660,110 shares issued and outstanding as of December 31, 2025.	493	266
Additional paid-in capital	84,775,498	79,457,010
Accumulated deficit	(80,870,065)	(73,233,896)
Total stockholders’ equity	3,905,926	6,223,380
Total liabilities and stockholders’ equity	$6,635,491	$7,863,826

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.